You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbinoxamine
Accession NumberDB00748  (APRD00765)
TypeSmall Molecule
GroupsApproved
Description

Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state “do not use” in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.

Structure
Thumb
Synonyms
(+-)-Carbinoxamine
{2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine
2-(P-chloro-alpha-(2-(dimethylamino)Ethoxy)benzyl)pyridine
Carbinoxamin
Carbinoxamina
Carbinoxamine
Carbinoxamine base
Carbinoxaminum
Paracarbinoxamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Karbinal ERsuspension, extended release4 mg/5mLoralFSC Laboratories, Inc2014-01-03Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arbinoxatablet4 mg/1oralHawthorn Pharmaceuticals, Inc.2010-08-23Not applicableUs
Arbinoxasolution.8 mg/mLoralHawthorn Pharmaceuticals, Inc.2011-04-01Not applicableUs
Carbinoxamine Maleatetablet4 mg/1oralBiocomp Pharma, Inc.2011-05-27Not applicableUs
Carbinoxamine Maleatetablet4 mg/1oralCypress Pharmaceutical, Inc.2010-08-23Not applicableUs
Carbinoxamine Maleatesyrup4 mg/5mLoralBreckenridge Pharmaceutical, Inc.2012-12-10Not applicableUs
Carbinoxamine Maleatetablet4 mg/1oralBreckenridge Pharmaceutical, Inc.2012-12-10Not applicableUs
Carbinoxamine Maleatesolution4 mg/5mLoralBoca Pharmacal, LLC2008-02-26Not applicableUs
Carbinoxamine Maleatesyrup4 mg/5mLoralMikart, Inc.2003-04-25Not applicableUs
Carbinoxamine Maleatetablet4 mg/1oralBoca Pharmacal, LLC2008-05-30Not applicableUs
Carbinoxamine Maleatetablet4 mg/1oralMikart, Inc.2003-03-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AllergefonSERP
ClistinNot Available
HistinKenyaku
KarbinalNot Available
RotoxamineNot Available
SatinminShou Chan
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Carbinoxamine Maleate
ThumbNot applicableDBSALT000963
Categories
UNII982A7M02H5
CAS number486-16-8
WeightAverage: 290.788
Monoisotopic: 290.118590947
Chemical FormulaC16H19ClN2O
InChI KeyInChIKey=OJFSXZCBGQGRNV-UHFFFAOYSA-N
InChI
InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
IUPAC Name
{2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine
SMILES
CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzylethers
Direct ParentBenzylethers
Alternative Parents
Substituents
  • Benzylether
  • Halobenzene
  • Chlorobenzene
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
PharmacodynamicsCarbinoxamine is a first generation antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, carbinoxamine competes with free histamine for binding at HA-receptor sites. Carbinoxamine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of carbinoxamine.
Mechanism of actionCarbinoxamine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Carbinoxamine's anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life10 to 20 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9787
Blood Brain Barrier+0.955
Caco-2 permeable+0.7503
P-glycoprotein substrateSubstrate0.6804
P-glycoprotein inhibitor INon-inhibitor0.5997
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.8203
CYP450 2D6 substrateSubstrate0.5558
CYP450 3A4 substrateSubstrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8452
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8403
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5557
Ames testNon AMES toxic0.8751
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9003 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7085
hERG inhibition (predictor II)Inhibitor0.6835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mcneil pharmaceutical co div mcneilab inc
  • Boca pharmacal inc
  • Cypress pharmaceutical inc
  • Mikart inc
  • Invagen pharmaceuticals inc
  • Ortho mcneil pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Solutionoral.8 mg/mL
Solutionoral4 mg/5mL
Syruporal4 mg/5mL
Tabletoral4 mg/1
Suspension, extended releaseoral4 mg/5mL
Prices
Unit descriptionCostUnit
Palgic 4 mg tablet0.87USD tablet
Carbinoxamine maleate 4 mg tablet0.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8062667 No2009-03-292029-03-29Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point160 °C at 1.00E-01 mm HgPhysProp
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.228 mg/mLALOGPS
logP3.03ALOGPS
logP3.27ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.36 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity82.13 m3·mol-1ChemAxon
Polarizability31.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0ab9-9200000000-c3abf61d5cdaa81de77dView in MoNA
References
Synthesis Reference

Tilford. C.H. and Shelton, R.S.; U.S. Patent 2,606,195;August 5,1952; assigned to The Wm.S. Merrell Company.
Swain, A.P.; U.S. Patent 2800,485; July 23,1957; assigned to McNeil Laboratories, Inc.

General References
  1. BEALE HD, RAWLING FF, FIGLEY KD: Clistin maleate; a clinical appraisal of a new antihistaminic. J Allergy. 1954 Nov;25(6):521-4. [PubMed:13211145 ]
External Links
ATC CodesR06AA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.6 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Carbinoxamine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Carbinoxamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carbinoxamine.
AbirateroneThe serum concentration of Carbinoxamine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Carbinoxamine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carbinoxamine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Carbinoxamine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carbinoxamine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carbinoxamine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carbinoxamine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Carbinoxamine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carbinoxamine.
AmiodaroneThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carbinoxamine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carbinoxamine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carbinoxamine.
AmoxapineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Carbinoxamine.
AmphetamineAmphetamine may decrease the sedative activities of Carbinoxamine.
AprepitantThe serum concentration of Carbinoxamine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.
ArmodafinilThe metabolism of Carbinoxamine can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Carbinoxamine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carbinoxamine.
AtazanavirThe metabolism of Carbinoxamine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Carbinoxamine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Carbinoxamine.
AzelastineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Carbinoxamine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carbinoxamine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Carbinoxamine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Carbinoxamine.
BenzphetamineBenzphetamine may decrease the sedative activities of Carbinoxamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carbinoxamine.
Benzylpenicilloyl PolylysineCarbinoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Carbinoxamine.
BexaroteneThe serum concentration of Carbinoxamine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Carbinoxamine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Carbinoxamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Carbinoxamine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
BrimonidineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Carbinoxamine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbinoxamine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Carbinoxamine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Carbinoxamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbinoxamine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Carbinoxamine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Carbinoxamine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Carbinoxamine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Carbinoxamine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carbinoxamine.
CapecitabineThe metabolism of Carbinoxamine can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Carbinoxamine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carbinoxamine.
CelecoxibThe metabolism of Carbinoxamine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Carbinoxamine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carbinoxamine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carbinoxamine.
ChloramphenicolThe metabolism of Carbinoxamine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbinoxamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Carbinoxamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carbinoxamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Carbinoxamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbinoxamine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carbinoxamine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carbinoxamine.
CholecalciferolThe metabolism of Carbinoxamine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Carbinoxamine can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbinoxamine.
CitalopramThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Citalopram.
CitalopramThe metabolism of Carbinoxamine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Carbinoxamine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Carbinoxamine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carbinoxamine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Carbinoxamine.
ClomipramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbinoxamine.
ClopidogrelThe metabolism of Carbinoxamine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carbinoxamine.
ClotrimazoleThe metabolism of Carbinoxamine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carbinoxamine.
CobicistatThe metabolism of Carbinoxamine can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Carbinoxamine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carbinoxamine.
ConivaptanThe serum concentration of Carbinoxamine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Carbinoxamine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.
CyclosporineThe metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Carbinoxamine.
Cyproterone acetateThe serum concentration of Carbinoxamine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Carbinoxamine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbinoxamine.
DapoxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapoxetine.
DarunavirThe metabolism of Carbinoxamine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Carbinoxamine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Carbinoxamine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Carbinoxamine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carbinoxamine.
DesipramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Carbinoxamine.
DexamethasoneThe serum concentration of Carbinoxamine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbinoxamine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Carbinoxamine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carbinoxamine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carbinoxamine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Carbinoxamine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carbinoxamine.
DifenoxinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carbinoxamine.
DihydroergotamineThe metabolism of Carbinoxamine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carbinoxamine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carbinoxamine.
DiltiazemThe metabolism of Carbinoxamine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carbinoxamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carbinoxamine.
DisulfiramThe metabolism of Carbinoxamine can be decreased when combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Carbinoxamine.
DoxepinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxepin.
DoxorubicinThe metabolism of Carbinoxamine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Carbinoxamine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
DoxylamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Carbinoxamine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
DronedaroneThe metabolism of Carbinoxamine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Carbinoxamine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Carbinoxamine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Carbinoxamine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Carbinoxamine.
EfavirenzThe serum concentration of Carbinoxamine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carbinoxamine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Carbinoxamine.
EnzalutamideThe serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Carbinoxamine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Carbinoxamine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Carbinoxamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbinoxamine.
EthanolCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Carbinoxamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.
EthotoinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carbinoxamine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carbinoxamine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carbinoxamine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Carbinoxamine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Carbinoxamine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Carbinoxamine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbinoxamine.
EtoperidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Carbinoxamine.
EtravirineThe serum concentration of Carbinoxamine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Felbamate.
FelodipineThe metabolism of Carbinoxamine can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carbinoxamine.
FenfluramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carbinoxamine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.
FexofenadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flibanserin.
FloxuridineThe metabolism of Carbinoxamine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Carbinoxamine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carbinoxamine.
FlunarizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carbinoxamine.
FluorouracilThe metabolism of Carbinoxamine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluoxetine.
FluoxetineThe metabolism of Carbinoxamine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carbinoxamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carbinoxamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carbinoxamine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carbinoxamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Carbinoxamine.
FluvastatinThe metabolism of Carbinoxamine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Carbinoxamine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Carbinoxamine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carbinoxamine.
Fusidic AcidThe serum concentration of Carbinoxamine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carbinoxamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Carbinoxamine.
GemfibrozilThe metabolism of Carbinoxamine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Carbinoxamine.
GuanfacineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Carbinoxamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Carbinoxamine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Carbinoxamine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carbinoxamine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbinoxamine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carbinoxamine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Carbinoxamine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Carbinoxamine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Iloperidone.
ImatinibThe metabolism of Carbinoxamine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Carbinoxamine.
IndalpineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Indalpine.
IndinavirThe metabolism of Carbinoxamine can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Carbinoxamine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Carbinoxamine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carbinoxamine.
IsoniazidThe metabolism of Carbinoxamine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Carbinoxamine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Carbinoxamine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Carbinoxamine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbinoxamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbinoxamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carbinoxamine.
KetoconazoleThe metabolism of Carbinoxamine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbinoxamine.
LapatinibThe metabolism of Carbinoxamine can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Carbinoxamine can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carbinoxamine.
LevocabastineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carbinoxamine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carbinoxamine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carbinoxamine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Carbinoxamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Carbinoxamine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Carbinoxamine.
LopinavirThe metabolism of Carbinoxamine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Carbinoxamine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbinoxamine.
LosartanThe metabolism of Carbinoxamine can be decreased when combined with Losartan.
LovastatinThe metabolism of Carbinoxamine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carbinoxamine.
Lu AA21004The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Carbinoxamine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Carbinoxamine can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Carbinoxamine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Carbinoxamine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Carbinoxamine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Carbinoxamine.
MephentermineMephentermine may decrease the sedative activities of Carbinoxamine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carbinoxamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carbinoxamine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Carbinoxamine.
MethamphetamineMethamphetamine may decrease the sedative activities of Carbinoxamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carbinoxamine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carbinoxamine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbinoxamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Carbinoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carbinoxamine.
MethsuximideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carbinoxamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Carbinoxamine.
MetyrosineCarbinoxamine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.
MifepristoneThe metabolism of Carbinoxamine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
MirtazapineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carbinoxamine.
MitotaneThe serum concentration of Carbinoxamine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Carbinoxamine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Carbinoxamine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Carbinoxamine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Carbinoxamine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
NabiloneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Nabilone.
NafcillinThe serum concentration of Carbinoxamine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carbinoxamine.
NefazodoneThe metabolism of Carbinoxamine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Carbinoxamine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Carbinoxamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Carbinoxamine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Carbinoxamine can be decreased when combined with Nicardipine.
NicotineThe metabolism of Carbinoxamine can be decreased when combined with Nicotine.
NilotinibThe metabolism of Carbinoxamine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carbinoxamine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Carbinoxamine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Carbinoxamine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbinoxamine.
OlanzapineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olanzapine.
OlaparibThe metabolism of Carbinoxamine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olopatadine.
OmeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carbinoxamine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Carbinoxamine.
OrphenadrineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carbinoxamine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Carbinoxamine.
OsimertinibThe serum concentration of Carbinoxamine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carbinoxamine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbinoxamine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carbinoxamine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carbinoxamine.
PalbociclibThe serum concentration of Carbinoxamine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbinoxamine.
PantoprazoleThe metabolism of Carbinoxamine can be decreased when combined with Pantoprazole.
ParaldehydeCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Carbinoxamine.
ParoxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine.
ParoxetineThe metabolism of Carbinoxamine can be decreased when combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carbinoxamine.
PerampanelThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Carbinoxamine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carbinoxamine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbinoxamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carbinoxamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Carbinoxamine.
PhenterminePhentermine may decrease the sedative activities of Carbinoxamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carbinoxamine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Carbinoxamine.
PioglitazoneThe metabolism of Carbinoxamine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carbinoxamine.
PipotiazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.
PosaconazoleThe metabolism of Carbinoxamine can be decreased when combined with Posaconazole.
PramipexoleCarbinoxamine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carbinoxamine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Carbinoxamine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbinoxamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Carbinoxamine.
PrimidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Carbinoxamine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.
PromethazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carbinoxamine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carbinoxamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Carbinoxamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Carbinoxamine.
PyrimethamineThe metabolism of Carbinoxamine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Carbinoxamine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.
QuinineThe metabolism of Carbinoxamine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ramelteon.
RanolazineThe metabolism of Carbinoxamine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carbinoxamine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carbinoxamine.
RifabutinThe metabolism of Carbinoxamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Carbinoxamine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Carbinoxamine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.
RitonavirThe metabolism of Carbinoxamine can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Carbinoxamine.
RopiniroleCarbinoxamine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine.
RosiglitazoneThe metabolism of Carbinoxamine can be decreased when combined with Rosiglitazone.
RotigotineCarbinoxamine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carbinoxamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carbinoxamine.
SaquinavirThe metabolism of Carbinoxamine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carbinoxamine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Carbinoxamine.
SertralineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sertraline.
SertralineThe metabolism of Carbinoxamine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbinoxamine.
SildenafilThe metabolism of Carbinoxamine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Carbinoxamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Carbinoxamine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Carbinoxamine.
SorafenibThe metabolism of Carbinoxamine can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Carbinoxamine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.
SulfadiazineThe metabolism of Carbinoxamine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Carbinoxamine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Carbinoxamine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbinoxamine.
SuvorexantThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Suvorexant.
TamoxifenThe metabolism of Carbinoxamine can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tasimelteon.
TelaprevirThe metabolism of Carbinoxamine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Carbinoxamine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbinoxamine.
TeriflunomideThe metabolism of Carbinoxamine can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carbinoxamine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carbinoxamine.
ThalidomideCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carbinoxamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carbinoxamine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Carbinoxamine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Carbinoxamine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carbinoxamine.
ThiotepaThe metabolism of Carbinoxamine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carbinoxamine.
TiagabineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tiagabine.
TicagrelorThe metabolism of Carbinoxamine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Carbinoxamine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Carbinoxamine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.
TocilizumabThe serum concentration of Carbinoxamine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Carbinoxamine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carbinoxamine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Carbinoxamine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carbinoxamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carbinoxamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbinoxamine.
TrazodoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Carbinoxamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbinoxamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbinoxamine.
TrimethoprimThe metabolism of Carbinoxamine can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carbinoxamine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Carbinoxamine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Carbinoxamine.
ValsartanThe metabolism of Carbinoxamine can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Carbinoxamine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vilazodone.
VoriconazoleThe metabolism of Carbinoxamine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Carbinoxamine.
ZafirlukastThe metabolism of Carbinoxamine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carbinoxamine.
ZiconotideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zimelidine.
ZiprasidoneThe metabolism of Carbinoxamine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Carbinoxamine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Carbinoxamine.
ZonisamideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Carbinoxamine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Carbinoxamine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbinoxamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. [PubMed:7513381 ]
  2. Ramadan AA, Mandil H: Spectrophotometric determination of carbinoxamine maleate in pharmaceutical formulations by ternary complex formation with Cu(II) and eosin. Anal Biochem. 2006 Jun 1;353(1):133-7. Epub 2006 Mar 9. [PubMed:16574052 ]
  3. Darby WJ: Nutrition, food needs and technologic priorities: the World Food Conference. Nutr Rev. 1975 Aug;33(8):225-34. [PubMed:1143714 ]
  4. Yang J, Dudley GB: [1,2]-Anionic rearrangement of 2-benzyloxypyridine and related pyridyl ethers. J Org Chem. 2009 Oct 16;74(20):7998-8000. doi: 10.1021/jo901707x. [PubMed:19761204 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:14